文献速递细菌感染、耐药与抗菌药物

淋球菌阿奇霉素仅敏感解释折点的依据

Rationale for a Neisseria gonorrhoeae Susceptible-only Interpretive Breakpoint for Azithromycin.
PubMed 文献 · Clin Infect Dis · 2020-01-01

本文总结了CLSI于2018年6月评审的依据数据,决定将淋球菌对阿奇霉素的敏感-only解释折点设定为最低抑菌浓度≤1 µg/mL。该折点也是流行病学 cutoff 值,并假定阿奇霉素1g单剂与头孢曲松250mg肌注单剂联合使用。折点有助于改善患者管理和监测,并支持未来FDA批准的现代化药敏试验开发。

要点

  • CLSI设定淋球菌阿奇霉素敏感-only折点为MIC≤1 µg/mL。
  • 该折点也是野生型分布上限的流行病学cutoff值。
  • 折点假定阿奇霉素1g单剂联合头孢曲松250mg肌注单剂使用。

核心结论

  • CLSI于2018年6月设定淋球菌阿奇霉素敏感-only解释折点为MIC≤1 µg/mL,该折点成为定义淋球菌阿奇霉素敏感性的公认标准。

研究设计与样本

  • 本文总结CLSI于2018年6月评审的依据数据,属于方法学与标准制定说明。

主要发现

  • CLSI决定将淋球菌阿奇霉素敏感-only解释折点设为MIC≤1 µg/mL,该值也是流行病学cutoff值(野生型敏感分布终点)。
  • 该折点假定阿奇霉素1g单剂用于包含头孢曲松250mg肌注单剂的获批方案。
  • 该折点与欧洲抗菌药物敏感性试验委员会移除原有不同阿奇霉素折点并以ECV作为检测指导的决定一致。

关键数值与推荐

  • 淋球菌对阿奇霉素的敏感-only解释折点为最低抑菌浓度≤1 µg/mL。
  • 该折点对应的流行病学cutoff值为野生型敏感分布终点。
  • 折点适用条件为阿奇霉素1g单剂联合头孢曲松250mg肌注单剂使用。

临床怎么用

  • 临床微生物实验室可使用CLSI敏感-only折点(MIC≤1 µg/mL)解释淋球菌阿奇霉素药敏结果。
  • 解释结果时应考虑折点假定阿奇霉素1g单剂与头孢曲松250mg肌注单剂联合使用。

局限性

  • 原文未报告折点制定所依据的具体研究数据、样本量或统计参数。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Azithromycin (AZI) is recommended with ceftriaxone (CRO) for treatment of uncomplicated gonococcal urethritis and cervicitis in the United States, and an AZI-susceptibility breakpoint is needed. Neither the Food and Drug Administration (FDA) nor the Clinical and Laboratory Standards Institute (CLSI) has set interpretive breakpoints for AZI susceptibility. As a result, AZI antimicrobial susceptibility testing (AST) cannot be interpreted using recognized standards. This has contributed to increasingly unavailable clinical laboratory AST, although gonorrhea is on the rise with >550 000 US gonorrhea cases reported to the Centers for Disease Control and Prevention in 2017, the highest number of cases since 1991. METHODS: This article summarizes the rationale data reviewed by the CLSI in June 2018. RESULTS: The CLSI decided to set a susceptible-only interpretive breakpoint at the minimum inhibitory concentration of ≤1 µg/mL. This is also the epidemiological cutoff value (ECV) (ie, the end of the wild-type susceptibility distribution). This breakpoint presumes that AZI (1-g single dose) is used in an approved regimen that includes an additional antimicrobial agent (ie, CRO 250 mg, intramuscular single dose). CONCLUSIONS: Having a breakpoint can improve patient care and surveillance and allow future development and FDA regulatory approval of modernized AST to guide treatment. The breakpoint coincides with a European Committee on AST decision to remove previously established, differing AZI breakpoints and use the ECV as guidance for testing. The CLSI breakpoint is now the recognized standard that defines AZI susceptibility for gonococcal infections.

来源:Clin Infect Dis,查看原文。版权归原作者所有。

引用

  1. Kersh EN, Allen V, Ransom E, et al. Rationale for a Neisseria gonorrhoeae Susceptible-only Interpretive Breakpoint for Azithromycin. Clin Infect Dis. 2020. PMID: 30963175. doi:10.1093/cid/ciz292

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。